Skip to main content
SpringerLink
Log in

Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction

How Strong is the Link?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

There are concerns that selective cyclo-oxygenase (COX)-2 inhibitors may be prothrombotic and increase the risk of myocardial infarction. This has largely arisen because of an unexpected finding of a higher rate of myocardial infarction in patients receiving rofecoxib compared with patients receiving naproxen in a study of gastrointestinal toxicity. The results of this study, a similar study of celecoxib versus ibuprofen or diclofenac, and data obtained from a meta-analysis of aspirin (acetylsalicylic acid) primary prevention trials suggest that differences in the rates of myocardial infarction between rofecoxib and naproxen may have been due to an unexpectedly low rate of myocardial infarction in patients receiving naproxen. However, population surveillance data also suggest that rofecoxib may be associated with a greater risk of myocardial infarction than celecoxib and certain nonselective nonsteroidal anti-inflammatory drugs. The magnitude of this increase in risk, if real, is uncertain but it is likely to be relatively small in patients for whom cardiovascular prophylaxis with aspirin is not indicated. Patients who require nonsteroidal anti-inflammatory therapy for arthritis and who are at high risk of cardiovascular disease should receive aspirin, probably in conjunction with selective COX-2 inhibitor therapy, as the risk of gastrointestinal ulceration may be lower than for aspirin plus a nonselective nonsteroidal anti-inflammatory drug. In patients who do not require aspirin for the prevention of cardiovascular events, the lower risk of gastrointestinal ulceration associated with COX-2 inhibitor compared with non-selective nonsteroidal anti-inflammatory drugs would be expected to outweigh any increase in the risk of myocardial infarction, if one exists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. Mukherjee D, Nissen S, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–9

    Article  PubMed  CAS  Google Scholar 

  2. Cleland LG, James MJ, Stamp LK, et al. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001; 175: 214–7

    PubMed  CAS  Google Scholar 

  3. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib vs nonsterioidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247–55

    Article  PubMed  CAS  Google Scholar 

  4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8

    Article  PubMed  CAS  Google Scholar 

  5. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000; 97: 10197–202

    Article  PubMed  CAS  Google Scholar 

  6. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenose (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272–7

    Article  PubMed  CAS  Google Scholar 

  7. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2 dependent prostaycyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840–5

    Article  PubMed  CAS  Google Scholar 

  8. Rodriguez LAG, Varas C, Patrona C. Differential effects of aspirin and non-aspirin non steroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382–7

    Article  Google Scholar 

  9. Ray WA, Stein CM, Hall K, et al. Nonsteroidal anti inflammatory drugs and risk of serious coronary heart disease; an observational cohort study. Lancet 2002; 359: 118–23

    Article  PubMed  CAS  Google Scholar 

  10. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–10

    Article  PubMed  CAS  Google Scholar 

  11. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–104

    Article  PubMed  CAS  Google Scholar 

  12. Rahme E, Pilote L, Le Lorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111–5

    Article  PubMed  CAS  Google Scholar 

  13. Aitchison KA, Coker SJ. Cyclooxygenase inhibition converts the effect of nitric oxide synthase inhibition from infarct size reduction to expansion in isolated rabbit hearts. J Molecular Cell Card 1999; 31: 1315–24

    Article  CAS  Google Scholar 

  14. Saito T, Rodger IW, Hu F, et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772–5

    Article  PubMed  CAS  Google Scholar 

  15. Cheng Y, Austin SC, Rocca B, et al. Role of protaclyclin in the cardiovascular response to thromboxane A2. Scientist 2002; 296: 539–41

    CAS  Google Scholar 

  16. Hennan JK, Huang J, Barret TO, et al. Effects of selective COX-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104: 820–5

    Article  PubMed  CAS  Google Scholar 

  17. Throckmorton DC. FDA Centre for Drug Evaluation and Research memorandum. Comparative safety of celecoxib, diclofenac and ibuprofen. FDA Celecoxib Renal/Cardiac Consultation 1.2.00, 2000; Rockville (MD)

    Google Scholar 

  18. Targum SL. Cardiovascular safety review. Rofecoxib. FDA NDA 21-042, S-007, 2001 Feb 8 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/as/01/briefing/3677b2_03_med.doc [Accessed 2002 Sep 12]

  19. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265–71

    Article  PubMed  CAS  Google Scholar 

  20. Hanson L, Zanchetti A, Curruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  Google Scholar 

  21. Koustam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials and rofecoxib. Circulation 2001; 104: 15–23

    Google Scholar 

  22. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal related adverse drug reactions between rofecoxib and celecoxib based on theWorld Health Organization/Uppsaala Monitoring Centre Safety Database. Clin Ther 2001 Sep; 23: 1478–91

    Google Scholar 

  23. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therapeut 2001; 8: 85–95

    Article  CAS  Google Scholar 

  24. McKenna F, Weaver A, Fiechtner JJ, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo controlled, randomised, double-blind study. J Clin Rheumatol 2001; 7: 151–9

    Article  PubMed  CAS  Google Scholar 

  25. McCarthy DM. Comparative toxicity of non-steroidal anti-inflammatory drugs. Am J Med 1999; 107(6A): 465–75

    Google Scholar 

Download references

Acknowledgements

Both authors have received sponsorship for educational and advisory activites from Merk Sharpe and Dohme, Pharmacia and Pfizer. No sources of funding were used to assist in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, St George Hospital, University of New South Wales, Gray Street, Kogarah, New South Wales, 2217, Australia

    Laurence G. Howes

  2. Department of Clinical Pharmacology, Alfred Hospital, Monash University, Prahan, Victoria, Australia

    Henry Krum

Authors
  1. Laurence G. Howes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Krum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence G. Howes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Howes, L.G., Krum, H. Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction. Drug-Safety 25, 829–835 (2002). https://doi.org/10.2165/00002018-200225120-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225120-00001

Keywords

Search

Navigation